PDCD1 and neoplasm: We then treated human PD-1-transgenic mice, implanted subcutaneously with Panc02-H7-Fluc tumours, with either 0.5 mg kg–1 PD1-IL2v, comprising the anti-human PD-1 antibody binder fused to IL-2v, or high-dose IL-2 (aldesleukin) as single agents or in combination with pembrolizumab.